APA (7th ed.) Citation

Liu, Q., Sheng, Y., Lin, F., Tan, H., Chang, Y., Lu, X., . . . Du, C. (2026). Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers. Cancers, 18(9), 1335. https://doi.org/10.3390/cancers18091335

Chicago Style (17th ed.) Citation

Liu, Qi, Yuling Sheng, Folan Lin, Haoyuan Tan, Yanyun Chang, Xiaopeng Lu, Hao Chen, and Changzheng Du. "Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers." Cancers 18, no. 9 (2026): 1335. https://doi.org/10.3390/cancers18091335.

MLA (9th ed.) Citation

Liu, Qi, et al. "Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers." Cancers, vol. 18, no. 9, 2026, p. 1335, https://doi.org/10.3390/cancers18091335.